Antibody-targeted T cells and natural killer cells for cancer immunotherapy.
Journal
Journal of nanobiotechnology
ISSN: 1477-3155
Titre abrégé: J Nanobiotechnology
Pays: England
ID NLM: 101152208
Informations de publication
Date de publication:
18 Oct 2024
18 Oct 2024
Historique:
received:
29
04
2024
accepted:
02
10
2024
medline:
19
10
2024
pubmed:
19
10
2024
entrez:
18
10
2024
Statut:
epublish
Résumé
Adoptive cell cancer therapies aim to re-engineer a patient's immune cells to mount an anti-cancer response. Chimeric antigen receptor T and natural killer cells have been engineered and proved successful in treating some cancers; however, the genetic methods for engineering are laborious, expensive, and inefficient and can cause severe toxicities when they over-proliferate. We examined whether the cell-killing capacity of activated T and NK cells could be targeted to cancer cells by anchoring antibodies to their cell surface. Using metabolic glycoengineering to introduce azide moieties to the cellular surface, we covalently attached a dibenzocyclooctyne-modified antibody using the strain-promoted alkyne azide cycloaddition reaction, creating antibody-conjugated T and NK cells. We targeted the immune cells to tumors possessing the xenoantigen, N-glycolyl neuraminic acid GM3 ganglioside, using the 14F7hT antibody. These activated T and NK cells are "armed" with tumour-homing capabilities that specifically lyses antigen-positive cancer cells without off-target toxicities. Moreover, when exposed to target cells, 14F7hT-conjugated T cells that are not preactivated exhibit increased perforin, granzyme, CD69, and CD25 expression and specific cell killing. This research shows the potential for a non-genetic method for redirecting cytotoxic immune cells as a feasible and effective approach for tumor-targeted cell immunotherapy.
Sections du résumé
BACKGROUND
BACKGROUND
Adoptive cell cancer therapies aim to re-engineer a patient's immune cells to mount an anti-cancer response. Chimeric antigen receptor T and natural killer cells have been engineered and proved successful in treating some cancers; however, the genetic methods for engineering are laborious, expensive, and inefficient and can cause severe toxicities when they over-proliferate.
RESULTS
RESULTS
We examined whether the cell-killing capacity of activated T and NK cells could be targeted to cancer cells by anchoring antibodies to their cell surface. Using metabolic glycoengineering to introduce azide moieties to the cellular surface, we covalently attached a dibenzocyclooctyne-modified antibody using the strain-promoted alkyne azide cycloaddition reaction, creating antibody-conjugated T and NK cells. We targeted the immune cells to tumors possessing the xenoantigen, N-glycolyl neuraminic acid GM3 ganglioside, using the 14F7hT antibody. These activated T and NK cells are "armed" with tumour-homing capabilities that specifically lyses antigen-positive cancer cells without off-target toxicities. Moreover, when exposed to target cells, 14F7hT-conjugated T cells that are not preactivated exhibit increased perforin, granzyme, CD69, and CD25 expression and specific cell killing.
CONCLUSIONS
CONCLUSIONS
This research shows the potential for a non-genetic method for redirecting cytotoxic immune cells as a feasible and effective approach for tumor-targeted cell immunotherapy.
Identifiants
pubmed: 39425222
doi: 10.1186/s12951-024-02898-3
pii: 10.1186/s12951-024-02898-3
doi:
Substances chimiques
Receptors, Chimeric Antigen
0
Antibodies
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
640Subventions
Organisme : Natural Sciences and Engineering Council of Canada
ID : 25634
Informations de copyright
© 2024. The Author(s).
Références
Barrett DM, Singh N, Porter DL, Grupp SA, June CH. Chimeric antigen receptor therapy for cancer. Annu Rev Med. 2014;65(1):333–47.
pubmed: 24274181
doi: 10.1146/annurev-med-060512-150254
Figueroa JA, Reidy A, Mirandola L, Trotter K, Suvorava N, Figueroa A, et al. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy. Int Rev Immunol. 2015;34(2):154–87.
pubmed: 25901860
doi: 10.3109/08830185.2015.1018419
Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–17.
pubmed: 25317870
pmcid: 4267531
doi: 10.1056/NEJMoa1407222
Santomasso B, Bachier C, Westin J, Rezvani K, Shpall EJ. The other side of CAR T-cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden. Am Soc Clin Oncol Educ Book. 2019;39:433–44.
pubmed: 31099694
doi: 10.1200/EDBK_238691
Shimabukuro-Vornhagen A, Gödel P, Subklewe M, Stemmler HJ, Schlößer HA, Schlaak M, et al. Cytokine release syndrome. J Immunother Cancer. 2018;6(1):56.
pubmed: 29907163
pmcid: 6003181
doi: 10.1186/s40425-018-0343-9
Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med. 2018;24(10):1499–503.
pubmed: 30275568
pmcid: 6511988
doi: 10.1038/s41591-018-0201-9
Irving M, Lanitis E, Migliorini D, Ivics Z, Guedan S. Choosing the right tool for genetic engineering: clinical lessons from chimeric antigen receptor-T cells. Hum Gene Ther. 2021;32(19–20):1044–58.
pubmed: 34662233
pmcid: 8697565
doi: 10.1089/hum.2021.173
Jackson HJ, Rafiq S, Brentjens RJ. Driving CAR T-cells forward. Nat Rev Clin Oncol. 2016;13(6):370–83.
pubmed: 27000958
pmcid: 5529102
doi: 10.1038/nrclinonc.2016.36
Abbina S, Siren EMJ, Moon H, Kizhakkedathu JN. Surface engineering for cell-based therapies: techniques for manipulating mammalian cell surfaces. ACS Biomater Sci Eng. 2018;4(11):3658–77.
pubmed: 33429616
doi: 10.1021/acsbiomaterials.7b00514
Stephan MT, Irvine DJ. Enhancing cell therapies from the outside in cell surface engineering using synthetic nanomaterials. Nano Today. 2011;6(3):309–25.
pubmed: 21826117
pmcid: 3148657
doi: 10.1016/j.nantod.2011.04.001
Wang Q, Cheng H, Peng H, Zhou H, Li PY, Langer R. Non-genetic engineering of cells for drug delivery and cell-based therapy. Adv Drug Deliv Rev. 2015;91:125–40.
pubmed: 25543006
doi: 10.1016/j.addr.2014.12.003
Kim NY, Park JH. Engineered immune cells with nanomaterials to improve adoptive cell therapy. Biomed Eng Lett. 2021;11(3):183–95.
pubmed: 34350047
pmcid: 8316519
doi: 10.1007/s13534-021-00197-6
Takayama Y, Kusamori K, Nishikawa M. Click chemistry as a tool for cell engineering and drug delivery. Molecules. 2019;24(1):172.
pubmed: 30621193
pmcid: 6337375
doi: 10.3390/molecules24010172
Fernández-Marrero Y, Roque-Navarro L, Hernández T, Dorvignit D, Molina-Pérez M, González A, et al. A cytotoxic humanized anti-ganglioside antibody produced in a murine cell line defective of N-glycolylated-glycoconjugates. Immunobiology. 2011;216(12):1239–47.
pubmed: 21802167
doi: 10.1016/j.imbio.2011.07.004
Malykh YN, Schauer R, Shaw L. N-glycolylneuraminic acid in human tumours. Biochimie. 2001;83(7):623–34.
pubmed: 11522391
doi: 10.1016/S0300-9084(01)01303-7
Samraj AN, Läubli H, Varki N, Varki A. Involvement of a non-human sialic acid in human cancer. Front Oncol. 2014;4:33. https://doi.org/10.3389/fonc.2014.00033 .
doi: 10.3389/fonc.2014.00033
pubmed: 24600589
pmcid: 3928833
Irie A, Koyama S, Kozutsumi Y, Kawasaki T, Suzuki A. The molecular basis for the absence of N-glycolylneuraminic acid in humans. J Biol Chem. 1998;273(25):15866–71.
pubmed: 9624188
doi: 10.1074/jbc.273.25.15866
Yin J, Hashimoto A, Izawa M, Miyazaki K, Chen GY, Takematsu H, et al. Hypoxic culture induces expression of Sialin, a sialic acid transporter, and cancer-associated gangliosides containing non-human sialic acid on human cancer cells. Cancer Res. 2006;66(6):2937–45.
pubmed: 16540641
doi: 10.1158/0008-5472.CAN-05-2615
Wang W, Zhao Z, Zhang Z, Zhang C, Xiao S, Ye X, et al. Redirecting killer T cells through incorporation of azido sugars for tethering ligands. ChemBioChem. 2017;18(21):2082–6.
pubmed: 28862366
doi: 10.1002/cbic.201700340
Liu CG, Wang Y, Liu P, Yao QL, Zhou YY, Li CF, et al. Aptamer-T cell targeted therapy for tumor treatment using sugar metabolism and click chemistry. ACS Chem Biol. 2020;15(6):1554–65.
pubmed: 32401486
doi: 10.1021/acschembio.0c00164
Hong S, Yu C, Wang P, Shi Y, Cao W, Cheng B, et al. Glycoengineering of NK cells with glycan ligands of CD22 and selectins for B-cell lymphoma therapy. Angew Chem Int Ed. 2021;60(7):3603–10.
doi: 10.1002/anie.202005934
Wang X, Lang S, Tian Y, Zhang J, Yan X, Fang Z, et al. Glycoengineering of natural killer cells with CD22 ligands for enhanced anticancer immunotherapy. ACS Cent Sci. 2020;6(3):382–9.
pubmed: 32232138
pmcid: 7099595
doi: 10.1021/acscentsci.9b00956
Yang S, Wen J, Li H, Xu L, Liu Y, Zhao N, et al. Aptamer-engineered natural killer cells for cell-specific adaptive immunotherapy. Small. 2019;15(22):1900903.
doi: 10.1002/smll.201900903
Zheng Y, Lai Z, Wang B, Wei Z, Zeng Y, Zhuang Q, et al. Natural killer cells modified with a Gpc3 aptamer enhance adoptive immunotherapy for hepatocellular carcinoma. Discov Onc. 2023;14(1):164.
doi: 10.1007/s12672-023-00780-6
Li J, Chen M, Liu Z, Zhang L, Felding BH, Moremen KW, et al. A single-step chemoenzymatic reaction for the construction of antibody-cell conjugates. ACS Cent Sci. 2018;4(12):1633–41.
pubmed: 30648147
pmcid: 6311947
doi: 10.1021/acscentsci.8b00552
Maza JC, García-Almedina DM, Boike LE, Hamlish NX, Nomura DK, Francis MB. Tyrosinase-mediated synthesis of nanobody-cell conjugates. ACS Cent Sci. 2022;8(7):955–62.
pubmed: 35912347
pmcid: 9335918
doi: 10.1021/acscentsci.1c01265
Wang X, Luo X, Tian Y, Wu T, Weng J, Li Z, et al. Equipping natural killer cells with cetuximab through metabolic glycoengineering and bioorthogonal reaction for targeted treatment of KRAS mutant colorectal cancer. ACS Chem Biol. 2021;16(4):724–30.
pubmed: 33829754
doi: 10.1021/acschembio.1c00022
Weltgesundheitsorganisation. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th edition. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. Lyon: International Agency for Research on Cancer; 2017. 585 p. (World Health Organization classification of tumours).
Gong JH, Maki G, Klingemann HG. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia. 1994;8(4):652–8.
pubmed: 8152260
Klingemann H. The NK-92 cell line—30 years later: its impact on natural killer cell research and treatment of cancer. Cytotherapy. 2023;25(5):451–7.
pubmed: 36610812
doi: 10.1016/j.jcyt.2022.12.003
Ying L, Xu J, Han D, Zhang Q, Hong Z. The applications of metabolic glycoengineering. Front Cell Dev Biol. 2022;10: 840831.
pubmed: 35252203
pmcid: 8892211
doi: 10.3389/fcell.2022.840831
Tangvoranuntakul P, Gagneux P, Diaz S, Bardor M, Varki N, Varki A, et al. Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. PNAS. 2003;100(21):12045–50.
pubmed: 14523234
pmcid: 218710
doi: 10.1073/pnas.2131556100
Böhmer RM, Bandala-Sanchez E, Harrison LC. Forward light scatter is a simple measure of T-cell activation and proliferation but is not universally suited for doublet discrimination. Cytometry. 2011;79A(8):646–52.
doi: 10.1002/cyto.a.21096
Ma Q, Wang Y, Lo ASY, Gomes EM, Junghans RP. Cell density plays a critical role in ex vivo expansion of T cells for adoptive immunotherapy. J Biomed Biotechnol. 2010;2010:1–13.
doi: 10.1155/2010/386545
Pollizzi KN, Waickman AT, Patel CH, Sun IH, Powell JD. Cellular size as a means of tracking mTOR activity and cell fate of CD4+ T cells upon antigen recognition. PLoS ONE. 2015;10(4): e0121710.
pubmed: 25849206
pmcid: 4388710
doi: 10.1371/journal.pone.0121710
Previte DM, O’Connor EC, Novak EA, Martins CP, Mollen KP, Piganelli JD. Reactive oxygen species are required for driving efficient and sustained aerobic glycolysis during CD4+ T cell activation. PLoS ONE. 2017;12(4): e0175549.
pubmed: 28426686
pmcid: 5398529
doi: 10.1371/journal.pone.0175549
Ribeiro A, Laranjeira P, Mendes S, Velada I, Leite C, Andrade P, et al. Mesenchymal stem cells from umbilical cord matrix, adipose tissue and bone marrow exhibit different capability to suppress peripheral blood B, natural killer and T cells. Stem Cell Res Ther. 2013;4(5):125.
pubmed: 24406104
pmcid: 3854702
doi: 10.1186/scrt336
Simonetti S, Natalini A, Folgori A, Capone S, Nicosia A, Santoni A, et al. Antigen-specific CD8 T cells in cell cycle circulate in the blood after vaccination. Scand J Immunol. 2019;89(2): e12735.
pubmed: 30488973
pmcid: 6850756
doi: 10.1111/sji.12735
Wu T, Luah YH, Luo Y, Womersley HJ, Cheow LF. Label-free lymphocytes reconstitution using side scatter for optimal T cell manufacturing. Immunology. 2020. https://doi.org/10.1101/2020.11.09.375584 .
doi: 10.1101/2020.11.09.375584
pubmed: 32913283
pmcid: 7692256
De Bousser E, Meuris L, Callewaert N, Festjens N. Human T cell glycosylation and implications on immune therapy for cancer. Hum Vaccin Immunother. 2020;16(10):2374–88.
pubmed: 32186959
pmcid: 7644206
doi: 10.1080/21645515.2020.1730658
Pereira MS, Alves I, Vicente M, Campar A, Silva MC, Padrão NA, et al. Glycans as key checkpoints of T cell activity and function. Front Immunol. 2018;9:2754.
pubmed: 30538706
pmcid: 6277680
doi: 10.3389/fimmu.2018.02754
Lin L, Couturier J, Yu X, Medina MA, Kozinetz CA, Lewis DE. Granzyme B secretion by human memory CD4 T cells is less strictly regulated compared to memory CD8 T cells. BMC Immunol. 2014;15(1):36.
pubmed: 25245659
pmcid: 4195902
doi: 10.1186/s12865-014-0036-1
Makedonas G, Banerjee PP, Pandey R, Hersperger AR, Sanborn KB, Hardy GAD, et al. Rapid up-regulation and granule-independent transport of perforin to the immunological synapse define a novel mechanism of antigen-specific CD8+ T cell cytotoxic activity. J Immunol. 2009;182(9):5560–9.
pubmed: 19380804
doi: 10.4049/jimmunol.0803945
Hersperger AR, Makedonas G, Betts MR. Flow cytometric detection of perforin upregulation in human CD8 T cells: detection of rapid perforin upregulation. Cytometry. 2008;73A(11):1050–7.
doi: 10.1002/cyto.a.20596
Hay ZLZ, Slansky JE. Granzymes: the molecular executors of immune-mediated cytotoxicity. IJMS. 2022;23(3):1833.
pubmed: 35163755
pmcid: 8836949
doi: 10.3390/ijms23031833
Moretti A, Ponzo M, Nicolette CA, Tcherepanova IY, Biondi A, Magnani CF. The past, present, and future of non-viral CAR T cells. Front Immunol. 2022;13: 867013.
pubmed: 35757746
pmcid: 9218214
doi: 10.3389/fimmu.2022.867013
Foster JB, Barrett DM, Karikó K. The emerging role of in vitro-transcribed mRNA in adoptive T cell immunotherapy. Mol Ther. 2019;27(4):747–56.
pubmed: 30819612
pmcid: 6453504
doi: 10.1016/j.ymthe.2019.01.018
Schaft N, Dörrie J, Schuler G, Schuler-Thurner B, Sallam H, Klein S, et al. The future of affordable cancer immunotherapy. Front Immunol. 2023;14:1248867.
pubmed: 37736099
pmcid: 10509759
doi: 10.3389/fimmu.2023.1248867
Zhao Z, Zheng L, Chen W, Weng W, Song J, Ji J. Delivery strategies of cancer immunotherapy: recent advances and future perspectives. J Hematol Oncol. 2019;12(1):126.
pubmed: 31779642
pmcid: 6883629
doi: 10.1186/s13045-019-0817-3
Zhang H, Zhao P, Huang H. Engineering better chimeric antigen receptor T cells. Exp Hematol Oncol. 2020;9(1):34.
pubmed: 33292660
pmcid: 7709221
doi: 10.1186/s40164-020-00190-2
Verhoeyen E, Costa C, Cosset FL. Lentiviral Vector Gene Transfer into Human T Cells. In: Baum C, editor. Genetic modification of hematopoietic stem cells. Totowa, NJ: Humana Press; 2009. p. 97–114. (Walker JM, editor. Methods in Molecular Biology, vol. 506). https://doi.org/10.1007/978-1-59745-409-4_8
Tumaini B, Lee DW, Lin T, Castiello L, Stroncek DF, Mackall C, et al. Simplified process for the production of anti–CD19-CAR–engineered T cells. Cytotherapy. 2013;15(11):1406–15.
pubmed: 23992830
pmcid: 4141724
doi: 10.1016/j.jcyt.2013.06.003
Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;129(25):3322–31.
pubmed: 28408462
pmcid: 5482103
doi: 10.1182/blood-2017-02-769208
Casati A, Varghaei-Nahvi A, Feldman SA, Assenmacher M, Rosenberg SA, Dudley ME, et al. Clinical-scale selection and viral transduction of human naïve and central memory CD8+ T cells for adoptive cell therapy of cancer patients. Cancer Immunol Immunother. 2013;62(10):1563–73.
pubmed: 23903715
pmcid: 6348480
doi: 10.1007/s00262-013-1459-x
Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–48.
pubmed: 29385370
pmcid: 5996391
doi: 10.1056/NEJMoa1709866
Park JH, Rivière I, Gonen M, Wang X, Sénéchal B, Curran KJ, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378(5):449–59.
pubmed: 29385376
pmcid: 6637939
doi: 10.1056/NEJMoa1709919
Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69.
pubmed: 33824268
pmcid: 8024391
doi: 10.1038/s41408-021-00459-7
Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 2018;8(10):1219–26.
pubmed: 30135176
doi: 10.1158/2159-8290.CD-18-0442